We assessed the therapeutic potential of [Pt(O,O’-acac)(γ-acac)(DMS)] in vivo using a xenograft model of breast cancer developed by injection of MCF-7 cells in the flank of BALB/c nude mice. Solid tumor-bearing mice showed up to 50% reduction of tumor mass after [Pt(O,O’-acac)(γ-acac)(DMS)] treatment, whereas an average 10% inhibition was recorded in cisplatin treated animals. Moreover, enhanced in vivo pharmacokinetics (PK), biodistribution and tolerability for [Pt(O,O’-acac)(γ-acac)(DMS)] administered Wistar rats have been observed with respect to cisplatin treated.
In vivo study on xenograft model: [Pt(O,O’-acac)(γ-acac)(DMS)] versus cisplatin
FANIZZI, Francesco Paolo;VETRUGNO, CARLA;MUSCELLA, Antonella;MIGONI, DANILO;DE PASCALI, SANDRA ANGELICA;MARSIGLIANTE, Santo
2013-01-01
Abstract
We assessed the therapeutic potential of [Pt(O,O’-acac)(γ-acac)(DMS)] in vivo using a xenograft model of breast cancer developed by injection of MCF-7 cells in the flank of BALB/c nude mice. Solid tumor-bearing mice showed up to 50% reduction of tumor mass after [Pt(O,O’-acac)(γ-acac)(DMS)] treatment, whereas an average 10% inhibition was recorded in cisplatin treated animals. Moreover, enhanced in vivo pharmacokinetics (PK), biodistribution and tolerability for [Pt(O,O’-acac)(γ-acac)(DMS)] administered Wistar rats have been observed with respect to cisplatin treated.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
